| Mindi Phillips, MA, CCC-SLP | |
|
90 Howard Dr, Shelbyville, KY 40065-8138 | |
| (502) 633-1007 | |
| (502) 437-0624 |
| Full Name | Mindi Phillips |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 90 Howard Dr, Shelbyville, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104914126 | NPI | - | NPPES |
| 891230100 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SA 8902 (Florida) | Secondary |
| 235Z00000X | Speech-language Pathologist | 140964 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mindi Phillips, MA, CCC-SLP 90 Howard Dr, Shelbyville, KY 40065-8138 Ph: (502) 633-1007 | Mindi Phillips, MA, CCC-SLP 90 Howard Dr, Shelbyville, KY 40065-8138 Ph: (502) 633-1007 |
News Archive
Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.
WHO is kicking off the Decade of Action for Road Safety 2021-2030 today in Geneva, with the ambitious target of preventing at least 50% of road traffic deaths and injuries by 2030.
PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.
The first U.S. patient to participate in a global study of a stem cell therapy injected directly into the brain to treat stroke disability was enrolled in the clinical trial this week at The University of Texas Health Science Center at Houston.
Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind presented October 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
› Verified 5 days ago
Mrs. Alyson K Kennon Woodyard, MS CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1871 Midland Trl, Shelbyville, KY 40065 Phone: 502-633-2454 | |
Leigh Beth Shafer, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Howard Dr, Shelbyville, KY 40065 Phone: 502-633-1007 | |
Katherine Bruton, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Howard Dr, Shelbyville, KY 40065 Phone: 502-633-1007 Fax: 502-437-0624 | |
Patrick A Davis, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Howard Dr, Shelbyville, KY 40065 Phone: 502-633-1007 | |
Tara Gwynn, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 90 Howard Dr, Shelbyville, KY 40065 Phone: 502-633-1007 Fax: 502-805-1511 | |
Miss Stephanie Lenae Stansky, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Howard Dr, Shelbyville, KY 40065 Phone: 502-633-1007 Fax: 502-437-0624 | |
Haley Morgan Ryan, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Howard Dr, Shelbyville, KY 40065 Phone: 502-633-1007 |